Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study / Efeitos do indacaterol versus tiotrópio na tolerância ao exercício em pacientes com DPOC moderada: estudo cruzado randomizado piloto

Abstract Objective: To compare a once-daily long-acting β2 agonist (indacaterol 150 µg) with a once-daily long-acting anticholinergic (tiotropium 5 µg) in terms of their effects on exercise endurance (limit of tolerance, Tlim) in patients with moderate COPD. Secondary endpoints were their effects on lung hyperinflation, exercise-related dyspnea, and daily-life dyspnea. Methods: This was a randomized, single-blind, crossover pilot study involving 20 patients (mean age, 60.9 ± 10.0 years; mean FEV1, 69 ± 7% of predicted). Spirometric parameters, Transition Dyspnea Index scores, Tlim, and exertional dyspnea were compared after three weeks of each treatment (with a one-week washout period between treatments). Results: Nineteen patients completed the study (one having been excluded because of COPD exacerbation). Improvement in Tlim from baseline tended to be greater after treatment with tiotropium than after treatment with indacaterol (96 ± 163 s vs. 8 ± 82 s; p = 0.06). Tlim significantly improved from baseline after treatment with tiotropium (having increased from 396 ± 319 s to 493 ± 347 s; p = 0.010) but not after treatment with indacaterol (having increased from 393 ± 246 to 401 ± 254 s; p = 0.678). There were no differences between the two treatments regarding improvements in Borg dyspnea scores and lung hyperinflation at "isotime" and peak exercise. There were also no significant differences between treatments regarding Transition Dyspnea Index scores (1.5 ± 2.1 vs. 0.9 ± 2.3; p = 0.39). Conclusions: In patients with moderate COPD, tiotropium tends to improve Tlim in comparison with indacaterol. No significant differences were observed between the two treatments regarding their effects on lung hyperinflation, exercise-related dyspnea, and daily-life dyspnea. Future studies, including a larger number of patients, are required in order to confirm our findings and explore mechanistic explanations. (ClinicalTrials.gov identifier: ...

RESUMO Objetivo: Comparar um β2-agonista de longa duração administrado uma vez por dia (indacaterol 150 µg) a um anticolinérgico de longa duração administrado uma vez por dia (tiotrópio 5 µg) quanto a seus efeitos na resistência ao exercício (limite de tolerância, Tlim) em pacientes com DPOC moderada. Os desfechos secundários foram seus efeitos na hiperinsuflação pulmonar, na dispneia causada pelo exercício e na dispneia na vida diária. Métodos: Estudo piloto randomizado cruzado e simples cego com 20 pacientes (média de idade: 60,9 ± 10,0 anos; média do VEF1: 69 ± 7% do previsto). Parâmetros espirométricos, pontuação no Transition Dyspnea Index, Tlim e dispneia aos esforços foram comparados após três semanas de cada tratamento (com uma semana de intervalo entre os tratamentos). Resultados: Dezenove pacientes completaram o estudo - um foi excluído por causa de exacerbação da DPOC. A melhora no Tlim tendeu a ser maior com tiotrópio do que com indacaterol (96 ± 163 s vs. 8 ± 82 s; p = 0,06). Em comparação com os valores basais, o Tlim melhorou significativamente com tiotrópio (aumentando de 396 ± 319 s para 493 ± 347 s; p = 0,010), mas não com indacaterol (aumentando de 393 ± 246 para 401 ± 254 s; p = 0,678). Não houve diferença entre os tratamentos quanto à melhora na pontuação na escala de dispneia de Borg e na insuflação pulmonar no "isotempo" e no pico do exercício. Também não houve diferenças significativas entre os tratamentos quanto à pontuação no Transition Dyspnea Index (1,5 ± 2,1 vs. 0,9 ± 2,3; p = 0,39). Conclusões: Em pacientes com DPOC moderada, o tiotrópio tende a melhorar o Tlim em comparação com o indacaterol. Não houve diferenças significativas entre os tratamentos quanto a seus efeitos na insuflação pulmonar, na dispneia durante o exercício e na dispneia na vida diária. São necessários mais estudos, com um número maior de pacientes, para confirmar nossos achados e explorar explicações mecanicistas. (ClinicalTrials.gov ...

Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder

We assessed the efficacy and tolerability of the augmentation of antidepressants (ATDs) with atypical antipsychotics (AAPs) to treat patients with major depressive disorder. A retrograde study to identify relevant patient data included databases of PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and Database of Abstracts of Reviews of Effects. Data from 17 trials, involving 3807 participants, were identified. The remission rate (RR) and overall response rate (ORR) of adjunctive treatment with AAPs were significantly higher than placebo treatment: RR=1.90 (95%CI=1.61-2.23, z=7.74, P<0.00001) and ORR=1.68 (95%CI=1.45-1.94, z=7.07, P<0.00001). We found that the short-term (4 weeks) treatment [ORR=1.70 (95%CI=0.98-2.95, Z=1.89, P=0.06)] was significantly different from the long-term (6-12 weeks) treatment [ORR=1.68 (95%CI=1.45-1.94, z=7.07, P<0.00001)]. No significant difference in ORR was observed between groups with or without sedative drugs. The discontinuation rate due to adverse effects was higher for adjunctive treatment with AAPs: ORR=3.32 (95%CI=2.35-4.70, z=6.78, P<0.00001). These results demonstrate that the augmentation of ATDs with AAPs (olanzapine, quetiapine, aripiprazole, and risperidone) was more effective than a placebo in improving response and remission rates, although associated with a higher discontinuation rate due to adverse effects.

Preventive Efficacy and Safety of Rebamipide in Nonsteroidal Anti-Inflammatory Drug-Induced Mucosal Toxicity

BACKGROUND/AIMS: The use of proton pump inhibitors or misoprostol is known to prevent the gastrointestinal complications of nonsteroidal anti-inflammatory drugs (NSAIDs). Rebamipide is known to increase the mucosal generation of prostaglandins and to eliminate free oxygen radicals, thus enhancing the protective function of the gastric mucosa. However, it is unknown whether rebamipide plays a role in preventing NSAID-induced gastropathy. The aim of this study was to determine the effectiveness of rebamipide compared to misoprostol in preventing NSAID-induced gastrointestinal complications in patients requiring continuous NSAID treatment. METHODS: We studied 479 patients who required continuous NSAID treatment. The patients were randomly assigned to groups that received 100 mg of rebamipide three times per day or 200 microg of misoprostol three times per day for 12 weeks. The primary endpoint of the analysis was the occurrence rate of gastric ulcers, as determined by endoscopy after 12 weeks of therapy. RESULTS: Of the 479 patients in the study, 242 received rebamipide, and 237 received misoprostol. Ultimately, 44 patients (18.6%) withdrew from the misoprostol group and 25 patients (10.3%) withdrew from the rebamipide group. There was a significant difference in withdrawal rate between the two groups (p=0.0103). The per protocol analysis set was not valid because of the dropout rate of the misoprostol group; thus, the intention to treat (ITT) analysis set is the main set for the efficacy analysis in this study. After 12 weeks, the occurrence rate of gastric ulcers was similar in the rebamipide and misoprostol groups (20.3% vs 21.9%, p=0.6497) according to ITT analysis. In addition, the therapeutic failure rate was similar in the rebamipide and misoprostol groups (13.6% vs 13.1%, p=0.8580). The total severity score of the gastrointestinal symptoms was significantly lower in the rebamipide group than in the misoprostol group (p=0.0002). The amount of antacid used was significantly lower in the rebamipide group than in the misoprostol group (p=0.0258). CONCLUSIONS: Rebamipide can prevent gastric ulcers when used with NSAIDs and can decrease the gastrointestinal symptoms associated with NSAID administration. When the possibility of poor compliance and the potential adverse effects of misoprostol are considered, rebamipide appears to be a clinically effective and safe alternative.

The Real Practice of Antibiotic Prophylaxis for Prostate Biopsy in Korea Where the Prevalence of Quinolone-Resistant Escherichia coli Is High

PURPOSE: Transrectal ultrasonography-guided prostate biopsy (TRUS-Bx) is an essential procedure for diagnosing prostate cancer. The American Urological Association (AUA) Guideline recommends fluoroquinolone alone for 1 day during TRUS-Bx. However, this recommendation may not be appropriate in regions where the prevalence of quinolone-resistant Escherichia coli is high. We investigated the real practice of antibiotic prophylaxis for TRUS-Bx in Korea. MATERIALS AND METHODS: A total of 77 hospitals performing TRUS-Bx were identified and an e-mail was sent to the Urology Department of those hospitals. The questions in the e-mail included the choice of antibiotics before and after the procedure and the duration of antibiotic therapy after TRUS-Bx. RESULTS: A total of 54 hospitals (70.0%) responded to the e-mail. Before TRUS-Bx, all hospitals administered intravenous antibiotic prophylaxis. The percentage of hospitals that used quinolone, cephalosporin, and aminoglycoside alone was 48.1%, 20.4%, and 9.3%, respectively. The percentage of hospitals that used two or more antibiotics was 22.2%. After biopsy, all 54 hospitals prescribed oral antibiotics. The percentage of hospitals that prescribed quinolone alone, cephalosporin alone, or a combination of two or more antibiotics was 77.8%, 20.4%, and 1.8%, respectively. The duration of antibiotic use was more than 3 days in most hospitals (79.6%). Only four hospitals (7.4%) followed the AUA recommendation of a 1-day regimen. CONCLUSIONS: The AUA recommendation was not followed by most hospitals in Korea. This clinical behavior might reflect the high quinolone resistance rate in Korea, and further studies on the most efficient prophylactic antibiotics after TRUS-Bx in Korea are warranted.

The Real Practice of Antibiotic Prophylaxis for Prostate Biopsy in Korea Where the Prevalence of Quinolone-Resistant Escherichia coli Is High

PURPOSE: Transrectal ultrasonography-guided prostate biopsy (TRUS-Bx) is an essential procedure for diagnosing prostate cancer. The American Urological Association (AUA) Guideline recommends fluoroquinolone alone for 1 day during TRUS-Bx. However, this recommendation may not be appropriate in regions where the prevalence of quinolone-resistant Escherichia coli is high. We investigated the real practice of antibiotic prophylaxis for TRUS-Bx in Korea. MATERIALS AND METHODS: A total of 77 hospitals performing TRUS-Bx were identified and an e-mail was sent to the Urology Department of those hospitals. The questions in the e-mail included the choice of antibiotics before and after the procedure and the duration of antibiotic therapy after TRUS-Bx. RESULTS: A total of 54 hospitals (70.0%) responded to the e-mail. Before TRUS-Bx, all hospitals administered intravenous antibiotic prophylaxis. The percentage of hospitals that used quinolone, cephalosporin, and aminoglycoside alone was 48.1%, 20.4%, and 9.3%, respectively. The percentage of hospitals that used two or more antibiotics was 22.2%. After biopsy, all 54 hospitals prescribed oral antibiotics. The percentage of hospitals that prescribed quinolone alone, cephalosporin alone, or a combination of two or more antibiotics was 77.8%, 20.4%, and 1.8%, respectively. The duration of antibiotic use was more than 3 days in most hospitals (79.6%). Only four hospitals (7.4%) followed the AUA recommendation of a 1-day regimen. CONCLUSIONS: The AUA recommendation was not followed by most hospitals in Korea. This clinical behavior might reflect the high quinolone resistance rate in Korea, and further studies on the most efficient prophylactic antibiotics after TRUS-Bx in Korea are warranted.

Experimental pleurodesis induced by antibiotics (macrolides or quinolones) / Pleurodese experimental induzida por antibióticos (macrolídeos e quinolonas)

PURPOSE: Chemical pleurodesis is a therapeutic tool for the treatment of recurrent pleural effusions, mainly those of neoplastic etiology. In the past, tetracycline was the sclerosant agent of choice in clinical practice, but presently, there is no consensus about an ideal agent. The aim of this study was to evaluate the effectiveness of macrolides (azithromycin and clarithromycin) or quinolones (levofloxacin and gatifloxacin) in inducing experimental pleurodesis in rabbits. METHOD: Forty New Zealand rabbits randomized into groups of 10 received (at a total volume of 2 mL for each animal) 1 of the 4 drugs by intrapleural injection. After 28 days, the animals were euthanized and the pleural cavity was evaluated macroscopically and microscopically. RESULTS: The intensity of the macroscopic adhesions was mild in all groups. On microscopic analysis, minimal pleural fibrosis and inflammation were observed in all animals. CONCLUSION: The macrolides (azithromycin or clarithromycin) and the quinolones (levofloxacin or gatifloxacin) when injected into the normal pleural space of rabbits are not effective in promoting pleurodesis. Additional research is required to identify sclerosing agents capable of inducing pleurodesis.

OBJETIVO: A pleurodese química representa uma ferramenta terapêutica utilizada no tratamento dos processos pleurais recidivantes, principalmente nos derrames neoplásicos. A escolha do melhor esclerosante pleural é ainda motivo de controvérsia, não havendo consenso com relação ao agente considerado ideal. O objetivo deste estudo é avaliar a efetividade dos macrolídeos (azitromicina e claritromicina) e das quinolonas (levofloxacina e gatifloxacina) na indução de pleurodese experimental em coelhos. MÉTODOS: Quarenta animais randomizados em grupos de 10, receberam, em volume total de 2 mL, estas drogas através de injeção intrapleural. RESULTADOS: Após 28 dias, os animais foram sacrificados sendo avaliada a cavidade pleural. A intensidade das aderências macroscópicas assim como da fibrose e da inflamação observadas à microscopia foi discreta tanto no grupo que recebeu macrolídeos quanto naquele que recebeu quinolonas. CONCLUSÃO: Azitromicina, Claritromicina, Levofloxacina e Gatifloxacina quando injetados na cavidade pleural de coelhos, não são eficazes na indução de pleurodese. Novas pesquisas devem ser realizadas com o intuito de identificar agentes esclerosantes capazes de produzir sínfise pleural.

Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis.

OBJECTIVE: To evaluate the efficacy and safety of 0.3% lomefloxacin single agent solution, by comparing to a combination of fortified ophthalmic solutions of cefazolin sodium 50 mg/ml and gentamicin sulfate 14 mg/ml, in the treatment of acute bacterial keratitis. DESIGN: Prospective, double-masked, randomized comparative trial. METHOD: Forty patients with clinical diagnosis of any grade of severity of acute bacterial keratitis were randomized into 2 treatment groups: 20 to fortified cefazolin-gentamicin group, and 20 to lomefloxacin-normal saline group. The dosing of the drugs were scheduled for both treatment groups as follows: 1 drop of each solution was alternately instilled every 5 minutes for the first 30 minutes (as loading dose), then 1 drop with 5-minute interval between 2 bottles instilled hourly for day 1-3, tapering to every 2 hours on day 4-6, and every 4 hours on day 7-14. After day 14, dosing discretion was clinically adjusted, based on the clinical condition and finally discontinued after complete healing. Corneal scraping for cultures was obtained before starting the treatment. Ocular symptoms and signs, time to heal and adverse reactions were evaluated and compared between the 2 groups on day 2, 4, 7, 14, 21 and 28. RESULTS: No clinically or statistically significant difference were noted between two treatment groups, regarding demographic, symptoms and signs associated with bacterial keratitis. Positive results of bacterial corneal cultures were obtained in 27.5%. There was no statistically significant difference in time to complete re-epithelialization in all types of bacterial keratitis (P=0.251). By day 7, the keratitis was healed: 44% in lomefloxacin group, and 33% in fortified antibiotic group. Both study medications were well-tolerated, with no incidence of reported adverse event. CONCLUSION: In this study, eventhough there is no statistically significant difference of symptoms and signs between the two study groups at any study visit, we found clinical improvement in all patients in lomefloxacin group. So, lomefloxacin may be used as an alternative to standard treatment in acute bacterial keratitis.

Comparison of topical lomefloxacin 0.3 per cent versus topical ciprofloxacin 0.3 per cent for the treatment of presumed bacterial corneal ulcers.

PURPOSE: To compare the efficacy and safety of topical lomefloxacin 0.3 per cent with topical ciprofloxacin 0.3 per cent for treating mildly severe suspected bacterial corneal ulcers. METHOD: This prospective, randomized, double-masked controlled clinical trial was conducted on 41 patients (41 eyes) with suspected bacterial corneal ulcers who were randomized into 2 groups: 23 patients were in the lomefloxacin group and 18 patients in the ciprofloxacin group. All of these corneal ulcers were scraped for gram's stain, KOH preparation and microbiologic cultures before starting treatment. The clinical success rate, the time to cure, the rates of treatment failures, ocular signs and symptoms and the adverse effects of the study medication were evaluated. RESULTS: Topical lomefloxacin is equivalent clinically and statistically to topical ciprofloxacin. No statistically significant treatment differences were found between lomefloxacin (100%) and ciprofloxacin (100%) in terms of success rate. Similarly, no differences were noted in the time to cure (p > 0.05), the treatment failure, or the resolution of the clinical signs and symptoms (p > 0.05). The adverse effects of lomefloxacin were superficial punctate keratitis (26.1%) and irritation (8.7%), whereas those of ciprofloxacin were superficial punctate keratitis (22.2%), white precipitate (11.1%) and irritation (11.1%). However, no statistically significant differences of these adverse effects were found between the two groups (p > 0.05). CONCLUSION: Lomefloxacin ophthalmic solution (0.3%) is equivalent clinically and statistically to ciprofloxacin ophthalmic solution (0.3%) for the treatment of mildly severe presumed bacterial corneal ulcers without statistically significant differences in the adverse effects and discomfort.

Treatment of necrotizing fasciitis with quinolones

To evaluate the effect of high dose quinolones therapy in patients with necrotizing fasciitis. Design: descriptive analytical study. Place and Duration of Study: the department of Plastic and reconstructive surgery, Hayatabad Medical complex, Peshawar, from January 2001 to March 2002. Subjects and Twenty consecutive patients, diagnosed with necrotizing fasciitis, were treated with intravenous quinolones [400 mg 8 hourly]. The response was evaluated in terms of subsidence of fever and C-reactive proteins levels. Majority of the patients was male [60%]. Lower limb involvement was most commonly involved [70%]. The most common initiating cause was injection abscess [45%]. Majority of the cultures showed polymicrobial infection [90%]. The most common isolate was streptococcus pyogenes [65%]. Majority of the patients showed excellent response with intravenous quinolones [Ciprofloxacin] in high doses in 24-48 hours. Only two patients [10%] failed to respond to therapy due to severe infection and delay in seeking treatment. Intravenous quinolones [Ciprofloxacin] in high doses are effective in controlling necrotizing soft tissue infections

Topical quinolones versus topical aminoglycosides in the medical management of chronic suppurative otitis media; A comparative trial

The objective of this clinical trial was to asses the efficacy of topical quinolones and compare it with the most commonly used aminoglycoside [gentamicin hydrocortisone] ear drops. Patients and methods: One hundred and twenty patients were recruited in this comparative clinical trial and divided into two groups: aminoglycoside group of 60 patients were treated with gentamycin hydrocortisone ear drops and quinolone group of 60 patients were prescribed norfloxacin topical solution with a dose of 6 drops in the affected ear twice daily for two weeks. In the aminoglycoside group 30 patients had complete cessation of the discharge, in 12 discharge decreased in amount and mucoid in nature and 18 had no change in the amount and nature of discharge. In the quinolone group in 43 patients discharge stopped completely, in 12 discharge reduced and became mucoid whereas in 5 no change in the amount and nature of the discharge occurred. We recommend that in the medical management of chronic suppurative otitis media, the topical quinolones should be considered first line of treatment as there are no ototoxic effects of quinolones, which can be used safely in the presence of tympanic membrane perforation

Effect of enrofloxacin on AgNOR counts in chick bone marrow nuclei.

The mAgNOR and pAgNOR counts reflecting the number of rDNA genes being transcribed, showed a highly significant increase from control values following administration of 5X, 10X, 15X doses of enrofloxacin in chicken. The maximum increase for both, mAgNOR and pAgNOR was shown by birds receiving 15X dose, sacrificed 48 hr after the last drug injection. The increase of pAgNOR at 5X (24 hr) was not significant relative to control values. After 72 hr time interval, AgNOR counts were not feasible due to poor differentiation. Values at 15X (24 hr) showed a decrease in number of AgNOR counts (non-significant) relative to 10X, probably due to depression of transcriptional activity of rDNA genes, which, however, is removed at 48 hr. The general increase in mAgNOR and pAgNOR with dose reflects hypertranscription of rDNA genes so that the birds can cope up with the drug induced toxicity.

Evaluation of minimum inhibitory concentration of quinolones and third generation cephalosporins to Salmonella typhi isolates.

A total of 323 Salmonella typhi isolates (261 isolates obtained during 1995-99 from Ludhiana and 62 randomly selected isolates obtained between 1980-99 from Chandigarh) were analyzed for drug resistant pattern. S. typhi isolates prior to 1986 were sensitive to all the antimicrobials tested by disc diffusion method. Most common multidrug resistance pattern noticed was ACCo T i.e. resistance to ampicillin, Chloramphenicol, cotrimoxazole and tetracycline. This study has revealed that withdrawal of chloramphenicol due to high level of resistance during 1990-94, has led to re-emergence of 43-93 percent chloramphenicol sensitive mutants during 1995-99. Two S. typhi isolates in 1995 and one in 1999 from Ludhiana depicted resistance to ciprofloxacin. Susceptibility of S. typhi isolates to third generation cephalosporins ranged between 87 to 100 per cent. There was a gradual increase with time period in mean minimum inhibitory concentration (MIC) of ciprofloxacin as it increased from 0.066 ug/ml for 1980-83 S. typhi isolates to 0.13 ug/ml for the 1996-99 isolates. Similarly, cefotaxime mean MIC for 1980-83 isolate was 0.172 ug/ml which further increased up to 0.32 ug/ml for S. typhi isolates encountered between 1996-99. In contrast, mean MIC value of 0.62 ug/ml of Ceftriaxone remained unchanged irrespective of the year of isolation of S. typhi isolates.

Chronic suppurative otitis Media: treatment with topical quinolone

Chronic suppurative otitis media is a common disease in low socio-economic group with high morbidity. DESIGN OF STUDY: Prospective study. To find out the efficacy of topical quinolones in chronic suppurative otitis media. SETITING: Department of ENT and Head and Neck surgery at Allied Hospital [PMC] Faisalabad. PERIOD: Jan 1998 to Sep 1999. PATIENTS AND METHODS: 100 patients were included in the study. Ears swabs were taken for culture sensitivity and those sensitive to chibromin were treated by topical preparation. Treatment was considered successful if a dry ear was achieved after two weeks treatment. Dry ear was obtained in more than 74% of the patients. CONCLUSIONS: Topical treatment is logical where site of infection if fairly easily accessible and high antibiotic concentration achieved at the site of infection could prevent emergence of resistant strains

Resistencia bacteriana del enterobacter a los antibióticos / Resistance of the enterobacter to antibiotics

Se evaluaron 113 cepas de Enterobacter spp. desde enero de 1995 hasta marzo de 1996, de seis laboratorios bacteriológicos, tres públicos y tres privados, obteniéndose 61 cepas, (53,98 por ciento) de Enterobacter aerogenes, 38 cepas (33,63 por ciento) de Enterobacter cloacae y 14 cepas (12,39 por ciento) de Enterobacter agglomerans, como resultados de cultivos de diversas fuentes, tales como secreción de heridas (34 por ciento), hemocultivos (26 por ciento), urocultivos (17 por ciento) y otros (23 por ciento). Ver Gráfico y Tabla 1. Se estudió el porcentaje de resistencia de distintas especies de Enterobacter, con discos de antibióticos, observandose una alta resistencia de las diferentes especies con ampicilina y cefalosporinas de primera generación. Se aprecia resistencia del Enterobacter cloacae al imipenem en un 3 por ciento de las cepas obtenidas, datos que concuerdan con los obtenidos a nivel nacional. Con respecto a los aminoglucósidos, llama la atención el alto porcentaje de resistencia obtenida a las diferentes especies de Enterobacter, mientras que con el ceftazidime, la resistencia del Enterobacter cloacae y del Enterobacter aerogenes cae significativamente, a diferencia de los datos obtenidos a nivel nacional, Las otras cefalosporinas (cefotaxina), cefoperazona, ceftriaxona) muestran datos variables de resistencia acordes a los datos nacionales a excepción de la cefoperazona, que muestra resistencias mayores. Se observó mayor eficacia con el uso de quinolonas, que representan el menor porcentaje de resistencias de las diferentes especies de Enterobacter, oscilando 5 y 9 por ciento

Estudio de eficacia y seguridad de ofloxacina en diversas infecciones bacterianas / Study of ofloxacin efficacy and safe in diversity

Se estudiarón 64 pacientes infectados con rango de edad entre 16 y 84 años, a quienes se les administró ofloxacina. Las enfermedades incluídas en el estudio fuerón: infección de partes blandas 41,93 por ciento, infección del tracto respiratorio inferior 26,8 por ciento, infecciones del tracto urinario 24,2 por ciento, y otras infecciones (sepsis, meningitis bacteriana, complicación post-parto y politraumatismo) 6,4 por ciento. De acuerdo al grado de severidad la distribución fue la siguiente: leves: 3,23 por ciento, moderadas: 51,61 por ciento y severas: 41,94 por ciento. El tratamiento con ofloxacina se administró en dosis promedio de 800 mg/día durante 3-17 días (promedio=9,75+3,37). La evolución clínica fue curación en el 83,87 por ciento, mejoría 12,90 por ciento (curación + mejoría = 96,7 por ciento), no determinada 3,22 por ciento y fracaso 0 por ciento. La evaluación de la eficacia bacteriológica mostró erradicación 70 por ciento, erradicación/superinfección 12 por ciento, persistencia 2 por ciento, resistencia 0 por ciento y no determinado 16 por ciento. La evaluación global del tratamiento fue clasificada como excelente en el 67,24 por ciento de los pacientes, buena 27,59 por ciento (excelente +buena =94,8 por ciento), regular 5,17 por ciento. Ningún paciente fue considerado con evolución inadecuada. En cuanto a la toxicidad de la droga, se registraron reacciones adversas: ardor local, nauseas, mareos, sudoración, acidez, insomnio y rash. Estas fueron clasificadas según su severidad en leve (2) moderada (2) y severa (1) este último caso ameritó la suspensión de la droga. En conclusión, ofloxacina puede considerarse eficaz y segura para el tratamiento de infecciones bacterinas

Las Quinolonas / The Quinolones

La continua lucha que el hombre libera contra gérmenes patógenos ha permitido obtener cada vez mejores y más eficaces antibióticos. Desde la década del sesenta el clínico dispone de un grupo de antimicrobianos que por sus características conforman un grupo especial: Las quinolonas. El entendimiento de su mecanismo de acción, actividad antimicrobiana, interacciones medicamentosas y otros aspectos son pilares básicos para que el médico comprenda y racionalice su uso. La inmensa gama de posibilidades de modificación en su molécula básica, indica que las quinolonas están llamadas a quedarse en el arsenal terapéutico durante varias décadas; de allí la importancia de revisar y actualizar los conceptos que hasta hoy rigen su uso clínico